With the latest Center for Drug Evaluation (CDE) announcement that eCTD will become mandatory across China in 2018, EXTEDO’s customers must have the best local support. “Besides our own office in Shanghai and our successful partnership with Neotrident China, our new partnership with Taimei Medical is another important milestone on the road to fulfilling the complex market requirements in China,” said Martin Schmid, CEO at EXTEDO.
Taimei will support EXTEDO’s solutions in the capacity of a Professional Partner. They will promote EXTEDO’s solutions in China and provide professional technical, consulting, and implementation services for local Life Sciences customers.
“Together with our partners, EXTEDO will be able to address the needs of Life Science organizations within the country and deliver the necessary software, solutions, and services designed to help streamline the registration process for pharmaceutical products. EXTEDO is proud to add Taimei to our portfolio of leading partnerships”, said Christian Bohrmann, VP Marketing & Alliances at EXTEDO.
About Taimei Medical Technology
Taimei comes with extensive experience, collaborating with over 200 local and global life science companies and CROs to meet China's increasingly complicated regulatory requirements. This is made possible by a multidisciplinary team of 300 employees, 40% of whom with solid working experience within the healthcare industry. Taimei provides high-quality professional services based on innovative technologies that reduce human labor and enhance efficiency to help clients optimize their value across life science product lifecycles.
%20Module.png)
